Clinical Trial Research

Trubion Pharmaceuticals, Inc. Reports Fourth Quarter and Year-Ended 2006 Financial Results and Provides 2007 Financial Outlook

Published in Biotech Business Week, April 9th, 2007

Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN), a biopharmaceutical company developing treatments for autoimmune disease and cancer, announced financial results for its fourth quarter and year-ended December 31, 2006, as well as 2007 financial guidance.

Fourth Quarter and Year 2006 Financial Results

Revenue for the fourth quarter of 2006 was $6.4 million compared to $222,000 for the fourth quarter of 2005. Revenue for the year-ended December 31, 2006 was $36.5 million compared to $349,000 for the year-ended December 31, 2005. Revenue in 2006 was earned through the company's strategic collaboration with Wyeth and consisted of collaborative research...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2007-04-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry